Building the bridge from drug discovery to clinical research using pathway approaches

International Drug Discovery

Volumn 2011, Issue 3, 2011, Pages 60-67

  Zhang, Litao ^a   Schweizer, Liang ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR;

ARTICLE; BIOLOGICAL PATHWAY; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CLINICAL RESEARCH; CRYSTALLIZATION; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; HISTORY; HUMAN; HUMAN GENOME; NONHUMAN; SIGNAL TRANSDUCTION;

EID: 79961016128     PISSN: 21504792     EISSN: 21504806     Source Type: Journal    
DOI: None     Document Type: Article

References (113)

1. Whitty, A. and M.H. Gelb, Critical challenges and emerging paradigms in drug discovery. Curr Opin Chem Biol, 2010. 14(4): p. 437-9.
2. Cole, P., Accelerating drug development and approval. Drug News Perspect, 2010. 23(1): p. 37-47.
3. Hughes, B., 2009 FDA drug approvals. Nat Rev Drug Discov, 2010. 9(2): p. 89-92.
4. DiMasi, J.A., et al., Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther, 2010. 87(3): p. 272-7.
5. Lipsky, M.S. and L.K. Sharp, From idea to market: the drug approval process. J Am Board Fam Pract, 2001. 14(5): p. 362-7.
6. Serajuddin, H.K. and A.T. Serajuddin, Value of pharmaceuticals: ensuring the future of research and development. J Am Pharm Assoc (2003), 2006. 46(4): p. 511-6.
7. Valentin, J.P. and T. Hammond, Safety and secondary pharmacology: successes, threats, challenges and opportunities. J Pharmacol Toxicol Methods, 2008. 58(2): p. 77-87.
8. Fields, S., Y. Kohara, and D.J. Lockhart, Functional genomics. Proc Natl Acad Sci U S A, 1999. 96(16): p. 8825-6.
9. Manis, J.P., Knock out, knock in, knock down--genetically manipulated mice and the Nobel Prize. N Engl J Med, 2007. 357(24): p. 2426-9.
10. Maxwell, M.M., RNAi applications in therapy development for neurodegenerative disease. Curr Pharm Des, 2009. 15(34): p. 3977-91.
11. Vidalin, O., et al., In vivo target validation using gene invalidation, RNA interference and protein functional knockout models: it is the time to combine. Curr Opin Pharmacol, 2009. 9(5): p. 669-76.
12. Roberts, S.A., High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica, 2001. 31(8-9): p. 557-89.
13. Houston, J.G., et al., Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006. Drug Discov Today, 2008. 13(1-2): p. 44-51.
14. Stewart, L., R. Clark, and C. Behnke, Highthroughput crystallization and structure determination in drug discovery. Drug Discov Today, 2002. 7(3): p. 187-96.
15. Deschamps, J.R., X-ray crystallography of chemical compounds. Life Sci, 2010. 86(15-16): p. 585-9.
16. Wang, J. and S. Skolnik, Recent advances in physicochemical and ADMET profiling in drug discovery. Chem Biodivers, 2009. 6(11): p. 1887-99.
17. Wan, H. and A.G. Holmen, High throughput screening of physicochemical properties and in vitro ADME profiling in drug discovery. Comb Chem High Throughput Screen, 2009. 12(3): p. 315-29.
18. Drewry, D.H. and R. Macarron, Enhancements of screening collections to address areas of unmet medical need: an industry perspective. Curr Opin Chem Biol, 2010. 14(3): p. 289-98.
19. Amore, B.M., J.P. Gibbs, and M.G. Emery, Application of in vivo animal models to characterize the pharmacokinetic and pharmacodynamic properties of drug candidates in discovery settings. Comb Chem High Throughput Screen, 2010. 13(2): p. 207-18.
20. Tiwari, A. and A.K. Sekhar, Workflow based framework for life science informatics. Comput Biol Chem, 2007. 31(5-6): p. 305-19.
21. Landry, Y. and J.P. Gies, Drugs and their molecular targets: an updated overview. Fundam Clin Pharmacol, 2008. 22(1): p. 1-18.
22. Sakharkar, M.K. and K.R. Sakharkar, Targetability of human disease genes. Curr Drug Discov Technol, 2007. 4(1): p. 48-58.
23. Hopkins, A.L. and C.R. Groom, The druggable genome. Nat Rev Drug Discov, 2002. 1(9): p. 727-30.
24. Hopkins, A.L. and G.R. Bickerton, Drug discovery: Know your chemical space. Nat Chem Biol, 2010. 6(7): p. 482-3.
25. Bickle, M., The beautiful cell: high-content screening in drug discovery. Anal Bioanal Chem, 2010. 398(1): p. 219-26.
26. Hargreaves, R.J., The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther, 2008. 83(2): p. 349-53.
27. Ramm, P., Image-based screening: a technology in transition. Curr Opin Biotechnol, 2005. 16(1): p. 41-8.
28. Mayr, L.M. and D. Bojanic, Novel trends in high-throughput screening. Curr Opin Pharmacol, 2009. 9(5): p. 580-8.
29. Liu, B., S. Li, and J. Hu, Technological advances in high-throughput screening. Am J Pharmacogenomics, 2004. 4(4): p. 263-76.
30. Entzeroth, M., Emerging trends in high-throughput screening. Curr Opin Pharmacol, 2003. 3(5): p. 522-9.
31. Sharff, A. and H. Jhoti, High-throughput crystallography to enhance drug discovery. Curr Opin Chem Biol, 2003. 7(3): p. 340-5.
32. Blundell, T.L. and S. Patel, High-throughput X-ray crystallography for drug discovery. Curr Opin Pharmacol, 2004. 4(5): p. 490-6.
33. Congreve, M., C.W. Murray, and T.L. Blundell, Structural biology and drug discovery. Drug Discov Today, 2005. 10(13): p. 895-907.
34. Hocquette, J.F., Where are we in genomics? J Physiol Pharmacol, 2005. 56 Suppl 3: p. 37-70.
35. Venter, J.C., et al., The sequence of the human genome. Science, 2001. 291(5507): p. 1304-51.
36. Subramanian, G., et al., Implications of the human genome for understanding human biology and medicine. Jama, 2001. 286(18): p. 2296-307.
37. Bansal, A.T. and M.R. Barnes, Genomics in drug discovery: the best things come to those who wait. Curr Opin Drug Discov Devel, 2008. 11(3): p. 303-11.
38. Galibert, F. and C. Andre, The dog genome. Genome Dyn, 2006. 2: p. 46-59.
39. Hancock, J.M., A bigger mouse? The rat genome unveiled. Bioessays, 2004. 26(10): p. 1039-42.
40. Houck, K.A. and R.J. Kavlock, Understanding mechanisms of toxicity: insights from drug discovery research. Toxicol Appl Pharmacol, 2008. 227(2): p. 163-78.
41. Sams-Dodd, F., Target-based drug discovery: is something wrong? Drug Discov Today, 2005. 10(2): p. 139-47.
42. Hellerstein, M.K., A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: advantages of pathway-based discovery. Metab Eng, 2008. 10(1): p. 1-9.
43. Hendriks, B.S., Functional pathway pharmacology: chemical tools, pathway knowledge and mechanistic modelbased interpretation of experimental data. Curr Opin Chem Biol, 2010. 14(4): p. 489-97.
44. Chuang, H.Y., M. Hofree, and T. Ideker, A decade of systems biology. Annu Rev Cell Dev Biol, 2010. 26: p. 721-44.
45. Nahorski, S.R., Pharmacology of intracellular signalling pathways. Br J Pharmacol, 2006. 147 Suppl 1: p. S38-45.
46. Watterson, S., S. Marshall, and P. Ghazal, Logic models of pathway biology. Drug Discov Today, 2008. 13(9-10): p. 447-56.
47. Baggs, J.E., M.E. Hughes, and J.B. Hogenesch, The network as the target. Wiley Interdiscip Rev Syst Biol Med, 2010. 2(2): p. 127-33.
48. Chen, G., et al., Applications of LC/MS in structure identifications of small molecules and proteins in drug discovery. J Mass Spectrom, 2007. 42(3): p. 279-87.
49. Heitzler, D., et al., Towards a systems biology approach of-G protein-coupled receptor signalling: challenges and expectations. C R Biol, 2009. 332(11): p. 947-57.
50. Hatch, M.D. and C.R. Slack, Photosynthesis by sugar-cane leaves. A new carboxylation reaction and the pathway of sugar formation. Biochem J, 1966. 101(1): p. 103-11.
51. Slack, C.R., M.D. Hatch, and D.J. Goodchild, Distribution of enzymes in mesophyll and parenchyma-sheath chloroplasts of maize leaves in relation to the C4-dicarboxylic acid pathway of photosynthesis. Biochem J, 1969. 114(3): p. 489-98.
52. Gonzalez-Vegas, J.A., Antagonism of dopamine-mediated inhibition in the nigro-striatal pathway: a mode of action of some catatonia-inducing drugs. Brain Res, 1974. 80(2): p. 219-28.
53. Fearon, D.T., K.F. Austen, and S. Ruddy, The properdin pathway: mechanisms of complement activation and analogies to the classical pathway. Rheumatology, 1975. 6: p. 2-16.
54. Bhat, G.J. and K.M. Baker, Cross-talk between angiotensin II and interleukin-6-induced signaling through Stat3 transcription factor. Basic Res Cardiol, 1998. 93 Suppl 3: p. 26-9.
55. Schweizer, L., et al., The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol, 2008. 9: p. 4.
56. Xu, C.X., H. Jin, and M.H. Cho, Apoptosis and apoptosis-based therapy in lung cancer. Anticancer Agents Med Chem, 2009. 9(9): p. 952-7.
57. Szabadkai, G. and M.R. Duchen, Mitochondria mediated cell death in diabetes. Apoptosis, 2009. 14(12): p. 1405-23.
58. Gorman, A.M., Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J Cell Mol Med, 2008. 12(6A): p. 2263-80.
59. Singh, S. and M. Dikshit, Apoptotic neuronal death in Parkinson's disease: involvement of nitric oxide. Brain Res Rev, 2007. 54(2): p. 233-50.
60. Yang, B.F., Y.J. Lu, and Z.G. Wang, MicroRNAs and apoptosis: implications in the molecular therapy of human disease. Clin Exp Pharmacol Physiol, 2009. 36(10): p. 951-60.
61. Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1): p. 57-70.
62. Zamore, P.D., et al., RNAi: doublestranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell, 2000. 101(1): p. 25-33.
63. Pei, Y. and T. Tuschl, On the art of identifying effective and specific siRNAs. Nat Methods, 2006. 3(9): p. 670-6.
64. Berns, K., et al., A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature, 2004. 428(6981): p. 431-7.
65. Hsieh, A.C., et al., A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Res, 2004. 32(3): p. 893-901.
66. Collins, C.S., et al., A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A, 2006. 103(10): p. 3775-80.
67. Blake, R.A., Target validation in drug discovery. Methods Mol Biol, 2007. 356: p. 367-77.
68. Yang, J.P., et al., A novel RNAi library based on partially randomized consensus sequences of nuclear receptors: identifying the receptors involved in amyloid beta degradation. Genomics, 2006. 88(3): p. 282-92.
69. Galvez, T., et al., siRNA screen of the human signaling proteome identifies the PtdIns(3,4,5)P3-mTOR signaling pathway as a primary regulator of transferrin uptake. Genome Biol, 2007. 8(7): p. R142.
70. Hattori, H., et al., RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells. Blood, 2007. 110(2): p. 640-50.
71. Evangelista, M., et al., Kinome siRNA screen identifies regulators of ciliogenesis and hedgehog signal transduction. Sci Signal, 2008. 1(39): p. ra7.
72. Major, M.B., et al., New regulators of Wnt/beta-catenin signaling revealed by integrative molecular screening. Sci Signal, 2008. 1(45): p. ra12.
73. Gaither, L.A., Chemogenomics approaches to novel target discovery. Expert Rev Proteomics, 2007. 4(3): p. 411-9.
74. Jansen, G., et al., Chemogenomic profiling predicts antifungal synergies. Mol Syst Biol, 2009. 5: p. 338.
75. Sos, M.L., et al., Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res, 2010. 70(3): p. 868-74.
76. Batova, M., et al., Chemogenomic and transcriptome analysis identifies mode of action of the chemosensitizing agent CTBT (7-chlorotetrazolo[5,1-c]benzo[1,2,4] triazine). BMC Genomics, 2010. 11: p. 153.
77. Blake, J.A., et al., The Mouse Genome Database (MGD). A comprehensive public resource of genetic, phenotypic and genomic data. The Mouse Genome Informatics Group. Nucleic Acids Res, 1997. 25(1): p. 85-91.
78. Blake, J.A., et al., The mouse genome database (MGD): premier model organism resource for mammalian genomics and genetics. Nucleic Acids Res, 2010.
79. Evsikov, A.V., et al., MouseCyc: a curated biochemical pathways database for the laboratory mouse. Genome Biol, 2009. 10(8): p. R84.
80. Itadani, H., S. Mizuarai, and H. Kotani, Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation. Curr Genomics, 2008. 9(5): p. 349-60.
81. Gatza, M.L., et al., A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A, 2010. 107(15): p. 6994-9.
82. Edwards, P.J., Value networks identify innovation in 21st century pharmaceutical research. Drug Discov Today, 2009. 14(1-2): p. 68-77.
83. Fischer, H.P., Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery. Biotechnol Annu Rev, 2005. 11: p. 1-68.
84. Lopez-Munoz, F. and C. Alamo, Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des, 2009. 15(14): p. 1563-86.
85. Ulitsky, I., et al., DEGAS: de novo discovery of dysregulated pathways in human diseases. PLoS One, 2010. 5(10): p. e13367.
86. Wu, Z., X.M. Zhao, and L. Chen, A systems biology approach to identify effective cocktail drugs. BMC Syst Biol, 2010. 4 Suppl 2: p. S7.
87. McCarty, M.F., Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther, 2004. 3(4): p. 349-80.
88. Aggarwal, B.B., et al., Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J Cell Biochem, 2007. 102(3): p. 580-92.
89. Michelini, E., et al., Cell-based assays: fuelling drug discovery. Anal Bioanal Chem, 2010. 398(1): p. 227-38.
90. Schindler, M., et al., Living in three dimensions: 3D nanostructured environments for cell culture and regenerative medicine. Cell Biochem Biophys, 2006. 45(2): p. 215-27.
91. Smalley, K.S., M. Lioni, and M. Herlyn, Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim, 2006. 42(8-9): p. 242-7.
92. Pickl, M. and C.H. Ries, Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene, 2009. 28(3): p. 461-8.
93. Toyli, M., et al., Different responses in transformation of MDCK cells in 2D and 3D culture by v-Src as revealed by microarray techniques, RT-PCR and functional assays. Lab Invest, 2010. 90(6): p. 915-28.
94. Kaakkola, S. and H. Teravainen, Animal models of parkinsonism. Pharmacol Toxicol, 1990. 67(2): p. 95-100.
95. Gaspo, R., The tachycardia-induced dog model of atrial fibrillation. clinical relevance and comparison with other models. J Pharmacol Toxicol Methods, 1999. 42(1): p. 11-20.
96. Guo, Y., et al., Understanding our drugs and our diseases. Proc Am Thorac Soc, 2006. 3(5): p. 409-12.
97. Steenbergen, P.J., M.K. Richardson, and D.L. Champagne, The use of the zebrafish model in stress research. Prog Neuropsychopharmacol Biol Psychiatry, 2010.
98. Penn, R.B., Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma. Naunyn Schmiedebergs Arch Pharmacol, 2008. 378(2): p. 149-69.
99. Kenakin, T.P., Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat Rev Drug Discov, 2009. 8(8): p. 617-26.
100. Mailman, R.B., GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci, 2007. 28(8): p. 390-6.
101. Gilchrist, A. and T. Blackmer, G-proteincoupled receptor pharmacology: examining the edges between theory and proof. Curr Opin Drug Discov Devel, 2007. 10(4): p. 446-51.
102. Hajdu, M., et al., Activity of the notchsignalling pathway in circulating human chronic lymphocytic leukaemia cells. Scand J Immunol, 2007. 65(3): p. 271-5.
103. Boran, A.D. and R. Iyengar, Systems pharmacology. Mt Sinai J Med, 2010. 77(4): p. 333-44.
104. Ho, R.L. and C.A. Lieu, Systems biology: an evolving approach in drug discovery and development. Drugs R D, 2008. 9(4): p. 203-16.
105. Chesne, C. and A. Guillouzo, Cryopreservation of isolated rat hepatocytes: a critical evaluation of freezing and thawing conditions. Cryobiology, 1988. 25(4): p. 323-30.
106. Li, A.P., Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem Biol Interact, 2007. 168(1): p. 16-29.
107. Nixon, A.J., G. Lust, and M. Vernier-Singer, Isolation, propagation, and cryopreservation of equine articular chondrocytes. Am J Vet Res, 1992. 53(12): p. 2364-70.
108. Stacey, G.N. and S. Dowall, Cryopreservation of primary animal cell cultures. Methods Mol Biol, 2007. 368: p. 271-81.
109. Eglen, R.M., A. Gilchrist, and T. Reisine, An overview of drug screening using primary and embryonic stem cells. Comb Chem High Throughput Screen, 2008. 11(7): p. 566-72.
110. Paynter, S.J., Principles and practical issues for cryopreservation of nerve cells. Brain Res Bull, 2008. 75(1): p. 1-14.
111. Takahashi, K. and S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006. 126(4): p. 663-76.
112. Takahashi, K., et al., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007. 131(5): p. 861-72.
113. Dimos, J.T., et al., Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science, 2008. 321(5893): p. 1218-21.